Professor Jerry Greenfield is an endocrinologist with primary clinical and research interests in the fields of type 1 and type 2 diabetes, insulin resistance, and obesity. He also has significant experience in treating other endocrine conditions, including thyroid disease and osteoporosis. Professor Greenfield is Head of Department of Endocrinology and Diabetes Services at St Vincent’s Hospital, and a Consultant Endocrinologist at St Vincent’s Private Hospital. Professor Greenfield is a Laboratory Head and Faculty Member at Victor Chang Cardiac Research Institute, and Professor, St Vincent’s Clinical Campus, School of Clinical Medicine, University of New South Wales. He has published over 200 peer-reviewed research papers in national and international medical journals.

So Hun Kim, M.D., Ph.D. is currently Professor of the Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea and the head of the department of Endocrinology and Metabolism at Inha University Hospital. She graduated from Yonsei University College of Medicine in 2000. She earned her Ph.D. at Yonsei University in 2008. After her intern, residency and fellowship at Severance Hospital she joined the division of endocrinology and metabolism, department of internal medicine of Inha University, Inha University Hospital since 2007. Her research focuses on complications of type 2 diabetes, including cardiovascular disease, diabetic kidney disease, and MASLD, lifestyle modification and metabolic syndrome. She is currently the Director of the Committee of International Liaison of the Korean Diabetes Association, a council member of the Korean Endocrine Society, Korean Society for the Study of Obesity, and Korean Association of Internal Medicine.

Professor Yan Bi is vice president of Nanjing Drum Tower Hospital and head of endocrinology. She is a distinguished talent of China’s National High-Level Talent Program, a lead expert for the National Science and Technology Major Project on chronic diseases, and a standing committee member of the Chinese Diabetes Society.

Shi Feiyan is a postgraduate student working under the supervision of Professor Ran Xingwu. Her research focuses on diabetic foot ulcers and their systemic cardiovascular complications, utilizing advanced imaging techniques to explore atherosclerosis in type 2 diabetes.

Samantha Hocking is an Endocrinologist at the Royal Prince Alfred Hospital and a Clinical Academic at the University of Sydney. Her main research interest is precision medicine exploring how personalised medicine can both predict, prevent and improve the management of metabolic disease, particularly diabetes.

Dr. Tannia Cyriac is a Research officer in the Exercise and Cardiovascular Research group at the University of Wollongong focused on lifestyle intervention clinical trials. With a background in Medicine and public health her research interests include cardiometabolic disease prevention and management, immunometabolism and adiposity.

Dr Joel Lasschuit (BMedSc, MBBS(Hons), FRACP, PhD) is an endocrinologist and researcher dedicated to improving outcomes for people with diabetes-related foot complications. He is a Staff Specialist in Endocrinology and Clinical Lead of High Risk Foot Services at St Vincent’s Hospital Sydney, and Manager of the Australian Diabetes Foot Registry.

Yu Ting Li is a Project Manager (Research and Community Outreach) at the Department of Preventive Ophthalmology at the Zhongshan Ophthalmic Center (ZOC), Sun Yat-Sen University. She has a multidisciplinary background in health management, public health, social work, and preventive ophthalmology.

Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington School of Medicine. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis. Her Nephrology fellowship training was performed at the University of Texas Health Science Center in San Antonio. Dr. Tuttle’s major research interests are in diabetes, chronic kidney disease (CKD), and cardiovascular-kidney-metabolic (CKM) syndrome. As a clinical and translational scientist, her seminal work in physiological and pre-clinical studies laid a foundation for advancing CKD and CKM therapies. Over more than three decades, she has led studies that delivered SGLT2 inhibitors and GLP-1 receptor agonists as novel agents to reduce risks of kidney failure, major adverse cardiovascular events, and premature mortality in populations with and without diabetes. She has also been a leading investigator for other breakthrough therapies for CKD and CKM conditions, including next generation incretin, anti-inflammatory, and aldosterone agents. Additionally, she leads the CURE-CKD Registry of real-world data for CKD, diabetes, and hypertension from >7 million health system patients. Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and was chair of the Diabetic Kidney Disease Collaborative, both for the American Society of Nephrology. She has also chaired many initiatives for the National Institutes of Health, the International Society of Nephrology, Kidney Disease Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two University of Washington School of Medicine Outstanding Clinical Faculty Awards.

Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington School of Medicine. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis. Her Nephrology fellowship training was performed at the University of Texas Health Science Center in San Antonio. Dr. Tuttle’s major research interests are in diabetes, chronic kidney disease (CKD), and cardiovascular-kidney-metabolic (CKM) syndrome. As a clinical and translational scientist, her seminal work in physiological and pre-clinical studies laid a foundation for advancing CKD and CKM therapies. Over more than three decades, she has led studies that delivered SGLT2 inhibitors and GLP-1 receptor agonists as novel agents to reduce risks of kidney failure, major adverse cardiovascular events, and premature mortality in populations with and without diabetes. She has also been a leading investigator for other breakthrough therapies for CKD and CKM conditions, including next generation incretin, anti-inflammatory, and aldosterone agents. Additionally, she leads the CURE-CKD Registry of real-world data for CKD, diabetes, and hypertension from >7 million health system patients. Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and was chair of the Diabetic Kidney Disease Collaborative, both for the American Society of Nephrology. She has also chaired many initiatives for the National Institutes of Health, the International Society of Nephrology, Kidney Disease Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two University of Washington School of Medicine Outstanding Clinical Faculty Awards.